Display options
Cite
Eissenberg LG, Rettig M, Dehdashti F, et al. Suicide genes: monitoring cells in patients with a safety switch. Front Pharmacol. 2014;5:241doi: 10.3389/fphar.2014.00241.
Eissenberg, L. G., Rettig, M., Dehdashti, F., Piwnica-Worms, D., & DiPersio, J. F. (2014). Suicide genes: monitoring cells in patients with a safety switch. Frontiers in pharmacology, 5241. https://doi.org/10.3389/fphar.2014.00241
Eissenberg, Linda G, et al. "Suicide genes: monitoring cells in patients with a safety switch." Frontiers in pharmacology vol. 5 (2014): 241. doi: https://doi.org/10.3389/fphar.2014.00241
Eissenberg LG, Rettig M, Dehdashti F, Piwnica-Worms D, DiPersio JF. Suicide genes: monitoring cells in patients with a safety switch. Front Pharmacol. 2014 Nov 06;5:241. doi: 10.3389/fphar.2014.00241. eCollection 2014. PMID: 25414668; PMCID: PMC4222135.
Copy Download .nbib Format: NLM
Share it on

Front Pharmacol. 2014 Nov 06;5:241. doi: 10.3389/fphar.2014.00241. eCollection 2014.

Suicide genes: monitoring cells in patients with a safety switch.

Frontiers in pharmacology

Linda G Eissenberg, Michael Rettig, Farrokh Dehdashti, David Piwnica-Worms, John F DiPersio

Affiliations

  1. Department of Internal Medicine, Washington University School of Medicine, St. Louis MO, USA.
  2. Department of Radiology, Washington University School of Medicine, St. Louis MO, USA.
  3. Department of Radiology, Washington University School of Medicine, St. Louis MO, USA ; Department of Cancer Systems Imaging, University of Texas MD Anderson Cancer Center Houston, TX, USA.

PMID: 25414668 PMCID: PMC4222135 DOI: 10.3389/fphar.2014.00241

Abstract

Clinical trials increasingly incorporate suicide genes either as direct lytic agents for tumors or as safety switches in therapies based on genetically modified cells. Suicide genes can also be used as non-invasive reporters to monitor the biological consequences of administering genetically modified cells to patients and gather information relevant to patient safety. These genes can monitor therapeutic outcomes addressable by early clinical intervention. As an example, our recent clinical trial used (18)F-9-(4-fluoro-3-hydroxymethylbutyl)guanine ((18)FHBG) and positron emission tomography (PET)/CT scans to follow T cells transduced with herpes simplex virus thymidine kinase after administration to patients. Guided by preclinical data we ultimately hope to discern whether a particular pattern of transduced T cell migration within patients reflects early development of graft vs. host disease. Current difficulties in terms of choice of suicide gene, biodistribution of radiolabeled tracers in humans vs. animal models, and threshold levels of genetically modified cells needed for detection by PET/CT are discussed. As alternative suicide genes are developed, additional radiolabel probes suitable for imaging in patients should be considered.

Keywords: PET-imaging; gene therapy; regenerative medicine; suicide gene; thymidine kinase; transplant biology

References

  1. Proc Natl Acad Sci U S A. 1996 Apr 16;93(8):3525-9 - PubMed
  2. J Cancer Res Ther (Manch). 2014;2(1):22-33 - PubMed
  3. Immunol Rev. 2014 Jan;257(1):165-80 - PubMed
  4. PLoS One. 2013 Oct 21;8(10):e77106 - PubMed
  5. Hum Gene Ther. 2008 Sep;19(9):937-50 - PubMed
  6. Lancet. 2001 Sep 1;358(9283):727-9 - PubMed
  7. Blood. 2006 Mar 15;107(6):2294-302 - PubMed
  8. Expert Rev Mol Med. 2012 Oct 15;14:e18 - PubMed
  9. J Nucl Med. 2007 May;48(5):819-26 - PubMed
  10. Blood. 2007 Jun 1;109(11):4708-15 - PubMed
  11. Gastroenterology. 2005 Jun;128(7):1787-95 - PubMed
  12. Nat Clin Pract Oncol. 2009 Jan;6(1):53-8 - PubMed
  13. J Biol Chem. 2012 Jan 2;287(1):446-54 - PubMed
  14. Exp Hematol. 2007 Dec;35(12):1823-38 - PubMed

Publication Types

Grant support